News

Technology allows partitioning of sequencing reads into 2 parental genome data sets.

According to the company, the software is designed to streamline the flow of information, surgical planning, and enable electronic medical record and diagnostic device integration.

This compound will be evaluated for the treatment of geographic atrophy (GA). The company shared that the first-in-human study is set to commence in 2024.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

According to the company, the clinical trial will assess the safety, efficacy and tolerability of AURN001, a combination cell therapy product.

Physician discusses 5 keys to achieve optimal results for patients

According to the company, AVD-104 is an engineered glycan (sialic acid) nanoparticle designed to target the self-pattern recognition receptors on overly activated retinal immune cells, specifically macrophages and microglia.

These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.

According to a study by a team of scientists led by Duke-NUS Medical School, pursuing fair AI for healthcare requires cross-disciplinary collaboration to translate methods into real-world benefits.

The company continues to turn to experts and leaders to support their mission and the development of new products through these appointments.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss 2 cases of CRAO immediate post-op uncomplicated cataract surgery under topical anesthesia treated with intra-ophthalmic artery fibrinolysis within 6 hours after symptom onset.

This gene therapy is designed to be a one-time intravitreally therapy that has demonstrated potent efficacy and a favorable safety profile in preclinical studies.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

Collaboration between ophthalmologists, optometrists can boost early detection.

This study will evaluate a potential gene therapy treatment in which a targeted gene directly to the retina.

According to a lawsuit filed in U.S. District Court in Detroit, a policy requires Henry Ford Health and Henry Ford Medical Group (HFMG) employees to undergo a screening assessment for cognition when they reach the age of 70, again at age 75 and each year after that.

According to Stuart, the agreement will grant Glaukos exclusive worldwide rights to develop and commercialize the company’s ST-113 drug candidate for neuroprotection in glaucoma.

The company made this decision after completing phase 2 trials of the drug.

Developing technology may offer marked improvements in surgical precision

The price tag of publishing presents a tricky research barrier

Thomas V. Johnson, MD, PhD, notes the value of home monitoring lies in its ability to provide real-time insights into IOP fluctuations, enabling more precise glaucoma care and a deeper understanding of the patient's risk for vision loss.

The FDA has granted temporary discretion to import erythromycin ophthalmic ointment for the treatment of newborns.

In the data shared, switching to SB15 from AFL maintained comparable clinical efficacy and safety in treating patients with neovascular age-related macular degeneration (nAMD), confirming biosimilarity between these agents before and after switching.

This effort will advance screening technology at Canada’s foremost specialist care provider in diabetes and endocrinology.

Orasis Pharmaceuticals announces approval of Qlosi, a preservative-free, low-dose eye drop for presbyopia, which consistently demonstrated efficacy, safety, and tolerability in two pivotal Phase 3 trials.

Orasis Pharmaceuticals CEO Elad Kedar and COO Paul Smith sat down with David Hutton to discuss the FDA approval of Qlosi, a preservative-free low-dose eyedrops for presbyopia.

Ocular graft-vs-host disease is not the garden variety dry eye.

Eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for the company.